2D Speckle Tracking Echocardiography, Breast Cancer, Cardiac Magnetic Resonance
Conditions
Brief summary
The field of oncology has advanced remarkably. Some of the old and new emerging cancer therapies are associated with development of cardiovascular toxicities , which may have the potential to offset the gains in survival obtained with this cancer treatment advances. Much of the focus on cardiovascular toxicities has been in the early detection of myocardial damage and prediction of cancer therapeutics-related cardiac dysfunction (CTRCD). The main strategy for these patients is timely diagnosis and treatment of high-risk individual Cardiac dysfunction associated with cancer treatment is the main cause of mortality in cancer survivors. The mortality rate is recorded to be up to 60% in the first two years after therapy. The most commonly associated drugs with cardiotoxicity are anthracycline (AC) and monoclonal antibodies (such as trastuzumab). Other new agents, such as vascular endothelial growth factor (VEGF) inhibitors, immunotherapies, and proteasome inhibitors, can also cause cardiac dysfunction .
Interventions
DEVICETwo dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging
2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment. 3D echo and CMR will be performed before and after chemotherapy treatment.
Sponsors
Assiut University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.
Exclusion criteria
* Contraindications to CMR (e.g.: patients with pacemakers, defibrillators or other implanted electronic devices). * Life expectancy ≤ 12 months. * Participating in another oncology clinical trial; * Prior exposure to chemotherapy; * History of active or prior cardiac disease (e.g., myocardial infarction, heart failure or base line left ventricular ejection fraction less than 55%).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine and compare the role of 2D speckle tracking vs. 3D echocardiography in assessment of early LV systolic dysfunction in patients receiving different chemotherapy combinations | up to 6 months after starting chemotherapy | All patient will be undergo both 2D and 3D echocardiography before and after treatment to detect early LV systolic dysfunction. |
Countries
Egypt
Contacts
Primary ContactJohn S Johny, MSC
Backup ContactShaima S Hassan, MD
Outcome results
None listed